Old West Investment Management boosts Apellis Pharmaceuticals holdings by 11%, now owning $3.6 million worth of stock.

Old West Investment Management LLC increased its holdings in Apellis Pharmaceuticals by 11%, buying 11,220 shares in Q4, according to its SEC filing. The fund now owns 113,623 shares, worth about $3.6 million, making up 1.5% of its portfolio. Apellis, a biopharmaceutical company focused on autoimmune and inflammatory diseases, has seen its stock receive a "Moderate Buy" rating with a target price of $45.59 from analysts.

6 days ago
3 Articles